Stifel analyst Annabel Samimy initiated coverage of Viking Therapeutics with a Buy rating and $22 price target, telling investors that the firm views the stock as "a stronger value proposition to play the NASH and obesity markets." VK2809 is approaching Phase 2b data with "a strong early profile of liver fat reduction, proven correlation with NASH/fibrosis reduction, and highly specific liver targeting that could offer better tolerability," the firm said.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on VKTX:
- Viking Therapeutics call volume above normal and directionally bullish
- William Blair biotech analysts to hold an analyst/industry conference call
- Viking Therapeutics price target raised to $20 from $17 at Oppenheimer
- Viking Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update
- Viking Therapeutics reports Q4 EPS (26c), consensus (23c)
